Oric Pharmaceuticals (ORIC) Liabilities and Shareholders Equity (2019 - 2026)

Oric Pharmaceuticals' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $436.8 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 79.84% year-over-year to $436.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 41.44% YoY) and the FY2025 annual result came in at $408.9 million, up 49.15% from the prior year.
• Liabilities and Shareholders Equity was $436.8 million for Q1 2026 at Oric Pharmaceuticals, up from $408.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $436.8 million in Q1 2026 and bottomed at $226.6 million in Q1 2023.
• A 5-year average of $305.1 million and a median of $275.1 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity slumped 30.77% — and 2026, when it soared 79.84%.
• Oric Pharmaceuticals' Liabilities and Shareholders Equity stood at $247.2 million in 2022, then climbed by 1.95% to $252.0 million in 2023, then grew by 8.78% to $274.1 million in 2024, then soared by 49.15% to $408.9 million in 2025, then climbed by 6.82% to $436.8 million in 2026.
• Business Quant data shows ORIC's Liabilities and Shareholders Equity at $436.8 million in Q1 2026, $408.9 million in Q4 2025, and $431.2 million in Q3 2025.